Cite
Cappello S, Sung HM, Ickes C, et al. Protein Signatures of NK Cell-Mediated Melanoma Killing Predict Response to Immunotherapies. Cancer Res. 2021;81(21):5540-5554doi: 10.1158/0008-5472.CAN-21-0164.
Cappello, S., Sung, H. M., Ickes, C., Gibhardt, C. S., Vultur, A., Bhat, H., Hu, Z., Brafford, P., Denger, A., Stejerean-Todoran, I., Köhn, R. M., Lorenz, V., Künzel, N., Salinas, G., Stanisz, H., Legler, T., Rehling, P., Schön, M. P., Lang, K. S., Helms, V., Herlyn, M., Hoth, M., Kummerow, C., & Bogeski, I. (2021). Protein Signatures of NK Cell-Mediated Melanoma Killing Predict Response to Immunotherapies. Cancer research, 81(21), 5540-5554. https://doi.org/10.1158/0008-5472.CAN-21-0164
Cappello, Sabrina, et al. "Protein Signatures of NK Cell-Mediated Melanoma Killing Predict Response to Immunotherapies." Cancer research vol. 81,21 (2021): 5540-5554. doi: https://doi.org/10.1158/0008-5472.CAN-21-0164
Cappello S, Sung HM, Ickes C, Gibhardt CS, Vultur A, Bhat H, Hu Z, Brafford P, Denger A, Stejerean-Todoran I, Köhn RM, Lorenz V, Künzel N, Salinas G, Stanisz H, Legler T, Rehling P, Schön MP, Lang KS, Helms V, Herlyn M, Hoth M, Kummerow C, Bogeski I. Protein Signatures of NK Cell-Mediated Melanoma Killing Predict Response to Immunotherapies. Cancer Res. 2021 Nov 01;81(21):5540-5554. doi: 10.1158/0008-5472.CAN-21-0164. Epub 2021 Sep 13. PMID: 34518212; PMCID: PMC8727679.
Copy
Download .nbib